Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer

European Journal of Cancer

Volumn 36, Issue SUPPL. 2, 2000, Pages 13-16

  Von Der Maase, H ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Advanced metastatic transitional cell carcinoma of the urothelium; Cisplatin; Gemcitabine; M VAC

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADVANCED CANCER; BLADDER CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; DRUG RESPONSE; HUMAN; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SHORT SURVEY; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT TUMOR; VOMITING;

EID: 0033948730     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(00)00080-0     Document Type: Short Survey

References (19)

1. Roth BJ. Chemotherapy for advanced bladder cancer. Semin Oncol 1996, 5, 633-644.
2. Scher HI, Bahnson R, Cohen S, et al. NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. Oncology 1998, 12, 225-271.
3. Dodd PM, McCaffrey JA, Herr H, et al. Outcome of post-chemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 1999, 17, 2546-2552.
4. Tannock I, Gospodarowicz M, Connolly J, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol 1989, 142, 289-292.
5. Igawa M, Ohkuchi T, Ueki T, et al. Usefulness and limitations for methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 1990, 144, 662-665.
6. Connor JP, Olsson CA, Benson MC, et al. Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern. Urology 1989, 34, 353-356.
7. Boutan-Laroze A, Mahjoubi M, Droz JP, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. Eur J Cancer 1991, 27A, 1690-1694.
8. Sternberg CN, de Mulder P, Fossa S, et al. Interim toxicity analysis of a randomized trial in advanced urothelial tract tumors of high-dose intensity M-VAC chemotherapy (HD-M-VAC) and recombinant human granulocyte colony-stimulating factor (G-CSF) versus classic M-VAC chemotherapy (EORTC 30924). Proc Am Soc Clin Oncol 1997, 16, 320a, abstract 1140.
9. Loehrer P, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group study. J Clin Oncol 1992, 10, 1066-1073.
10. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990, 8, 1050-1055.
11. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group study. J Clin Oncol 1997, 15, 2564-2569.
12. Pollera CF, Ceribelli A, Crecco M, et al. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994, 5, 182-184.
13. Lorusso V, Pollera CF, Antimi M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer 1998, 34, 1208-1212.
14. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997, 15, 3394-3398.
15. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997, 15, 3441-3445.
16. von der Maase H, Andersen L, Crino L, Weinknecht S, Dogliotti L. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol 1999, 10, 1461-1465.
17. Kaufman D, Stadler W, Carducci M, et al. Gemcitabine (GEM) plus cisplatin (CDDP) in metastatic transitional cell carcinoma (TCC): final results of a phase II study. Proc Am Soc Clin Oncol 1998, 17, 320a, abstract 1235.
18. Moore JM, Winquist EW, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999, 17, 2876-2881.
19. Mancarella S, Lorusso V, Manzione L, et al. Gemcitabine/ cisplatin in advanced transitional cell carcinoma of the urinary tract (TCC): a phase II multicenter trial. Eur J Cancer 1999, 35 (Suppl. 4), S347, abstract 1405.